Intranasal drug delivery: opportunities and toxicologic challenges during drug development

被引:349
作者
Keller, Lea-Adriana [1 ,2 ]
Merkel, Olivia [2 ]
Popp, Andreas [1 ]
机构
[1] AbbVie Deutschland GmbH & Co KG, Preclin Safety, Knollstr, D-67061 Ludwigshafen, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Pharm Pharmaceut Technol & Biopharm, Butenandtstr 5-13, D-81337 Munich, Germany
关键词
Intranasal drug delivery; Olfactory pathways; Nose-to-brain-delivery; Nasal toxicity; NASAL MUCOCILIARY CLEARANCE; GERM AGGLUTININ-HORSERADISH; CILIARY BEAT FREQUENCY; CENTRAL-NERVOUS-SYSTEM; RAT OLFACTORY SYSTEM; BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; STEM-CELLS; BENZALKONIUM CHLORIDE; RESPIRATORY MUCOSA;
D O I
10.1007/s13346-020-00891-5
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development.
引用
收藏
页码:735 / 757
页数:23
相关论文
共 260 条
[1]   Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region [J].
Agrawal, Mukta ;
Saraf, Swarnlata ;
Saraf, Shailendra ;
Antimisiaris, Sophia G. ;
Hamano, Nobuhito ;
Li, Shyh-Dar ;
Chougule, Mahavir ;
Shoyele, Sunday A. ;
Gupta, Umesh ;
Ajazuddin ;
Alexander, Amit .
EXPERT OPINION ON DRUG DELIVERY, 2018, 15 (06) :589-617
[2]   EFFECT OF OXYMETAZOLINE ON NASAL AND SINUS MUCOSAL BLOOD-FLOW IN THE RABBIT AS MEASURED WITH LASER-DOPPLER FLOWMETRY [J].
AKERLUND, A ;
BENDE, M ;
ARFORS, KE ;
INTAGLIETTA, M .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1993, 102 (02) :123-126
[3]   Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease [J].
Alarcon-Aris, Diana ;
Recasens, Ariadna ;
Galofre, Mireia ;
Carballo-Carbajal, Iria ;
Zacchi, Nicolas ;
Ruiz-Bronchal, Esther ;
Pavia-Collado, Ruben ;
Chica, Rosario ;
Ferres-Coy, Albert ;
Santos, Marina ;
Revilla, Raquel ;
Montefeltro, Andres ;
Farinas, Isabel ;
Artigas, Francesc ;
Vila, Miguel ;
Bortolozzi, Analia .
MOLECULAR THERAPY, 2018, 26 (02) :550-567
[4]   The effect of antiallergic intranasal formulations on ciliary beat frequency of human nasal epithelium in vitro [J].
Alberty, J ;
Stoll, W .
ALLERGY, 1998, 53 (10) :986-989
[5]   Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial [J].
Anagnostou, Evdokia ;
Soorya, Latha ;
Chaplin, William ;
Bartz, Jennifer ;
Halpern, Danielle ;
Wasserman, Stacey ;
Wang, A. Ting ;
Pepa, Lauren ;
Tanel, Nadia ;
Kushki, Azadeh ;
Hollander, Eric .
MOLECULAR AUTISM, 2012, 3
[6]  
[Anonymous], 1938, BRIT MED J, V1938, P953
[7]  
[Anonymous], CODE FEDERAL REGULAT
[8]  
Ansari MA, 2020, CURR PHARM DESIGN, V26, P1128, DOI [10.2174/1381612826666200116113912, 10.2174/1381612826666200116153912]
[9]   CENTRAL PROJECTIONS OF TRIGEMINAL PRIMARY AFFERENTS INNERVATING THE NASAL-MUCOSA - A HORSERADISH-PEROXIDASE STUDY IN THE RAT [J].
ANTON, F ;
PEPPEL, P .
NEUROSCIENCE, 1991, 41 (2-3) :617-628
[10]  
AOKI J, 1994, J BIOL CHEM, V269, P8431